First-In-Human Dose-Escalation Study of STP1002 in Patients With Advanced-Stage Solid Tumors
Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multicenter, dose-escalation study to evaluate the safety,
tolerability, and pharmacokinetics (PK) and to determine the maximum tolerated dose (MTD) of
STP1002 in patients with advanced-stage solid tumors.